Comparative Pharmacology
Head-to-head clinical analysis: CYCLOPAR versus MAOLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOPAR versus MAOLATE.
CYCLOPAR vs MAOLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclopar (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
MAOLATE is a centrally acting muscle relaxant that does not directly relax skeletal muscle. Its mechanism of action is not fully understood, but it is thought to act via inhibition of polysynaptic reflexes at the spinal level and possibly through sedation.
500 mg orally twice daily for 7-14 days.
250 mg orally 4 times daily or 500 mg orally 3 times daily for 21 days; maximum daily dose 2000 mg.
None Documented
None Documented
4-6 hours in normal renal function; prolonged to 12-24 hours in moderate impairment; up to 48 hours in severe impairment
Terminal elimination half-life: 8-12 hours (prolonged in renal impairment, up to 20-30 hours in severe renal failure; dose adjustment required for CrCl <30 mL/min)
Renal (80-90% unchanged), fecal (10-20%)
Renal: ~70% as unchanged drug and metabolites; Biliary/Fecal: ~30%
Category C
Category C
Muscle Relaxant
Muscle Relaxant